Inovio COVID vaccine leans toward T cell responses: Data Byte
Phase I data for Inovio’s COVID-19 vaccine suggest INO-4800 may stimulate T cell responses more potently than neutralizing responses. The preliminary readout also provided evidence the DNA vaccine induces both CD4+ and CD8+ memory T cell responses.
The company, which announced the data Thursday, ticked up $0.19 to $10.07 Thursday before giving back the gains on Monday, when its shares fell $0.66 to $9.60.
The tepid market reception suggests that, as in June when shares of Inovio Pharmaceuticals Inc. (NASDAQ:INO) lost 15% with the announcement of “overall immune responses” in 94% of trial participants at week six that investors see neutralization titers as the key benchmark of COVID-19 immunity.
The data, published on Dec. 24 in EClinicalMedicine, show prime-boost administration of 2 µg INO-4800 led to strong T cell responses against the SARS-CoV-2 spike protein at week eight vs. baseline in all 19 evaluable subjects, and induced neutralizing antibodies in 16 (84%) of them.
The study also evaluated prime-boost administration of 1 µg INO-4800. The lower dose led to lower humoral and cellular response rates but higher neutralization titers than the 2 µg dose.